{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:50:35Z","timestamp":1795038635090,"version":"4.10.2"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gonorrhoea is a prevalent sexually transmitted infection caused by the bacterial pathogen\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    .\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    has demonstrated a remarkable capacity to evolve antibiotic resistance, with emerging strains that show resistance to all standard treatment options. The development of new antibiotics for gonorrhoea, especially those with novel targets and no pre-existing resistance, is critical. One such untapped antibacterial target in\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    is FabI, an enoyl-acyl carrier protein reductase enzyme that is essential for fatty acid biosynthesis in this pathogen. In the current report, structure-based drug design using novel\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    FabI inhibitor co-crystals guides medicinal chemistry toward increasing potency in the sub-nanomolar range and drives the discovery of Debio 1453. Debio 1453 is optimized for activity against\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    and is highly active in vitro against diverse\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    isolates including those resistant to the last remaining treatment options. Additionally, the compound presents a low propensity for selection of mutants with reduced susceptibility. Debio 1453 is efficacious in vivo against\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    isolates with clinically relevant multi-drug resistance phenotypes in a murine vaginal gonorrhoea infection model underscoring Debio 1453 as a promising candidate for the treatment of gonorrhoea.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-63508-w","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:03:41Z","timestamp":1758186221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivo"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4583-8733","authenticated-orcid":false,"given":"Vincent","family":"Gerusz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Regenass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9084-2696","authenticated-orcid":false,"given":"Xavier","family":"Lav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shampa","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2289-2545","authenticated-orcid":false,"given":"Jos\u00e9e","family":"Hue Perron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Fajas Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenna\u00eblle","family":"Dieppois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nachum","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lefebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Altomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Romanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Daram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lysek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danig","family":"Pohin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Tatsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihiro","family":"Sunose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-5316","authenticated-orcid":false,"given":"C\u00e9line","family":"Ronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Ciesielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Ahlstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-2081","authenticated-orcid":false,"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-5625","authenticated-orcid":false,"given":"David R.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"63508_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","volume":"22","author":"JS Jensen","year":"2024","unstructured":"Jensen, J. S. & Unemo, M. Antimicrobial treatment and resistance in sexually transmitted bacterial infections. Nat. Rev. Microbiol. 22, 435\u2013450 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"63508_CR2","first-page":"1868","volume":"349","author":"MS Cohen","year":"1997","unstructured":"Cohen, M. S. et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Res. Group. Lancet 349, 1868\u20131873 (1997).","journal-title":"AIDSCAP Malawi Res. Group. Lancet"},{"key":"63508_CR3","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1093\/infdis\/jiab031","volume":"224","author":"T Darville","year":"2021","unstructured":"Darville, T. Pelvic inflammatory disease due to Neisseria gonorrhoeae and Chlamydia trachomatis: Immune evasion mechanisms and pathogenic disease pathways. J. Infect. Dis. 224, S39\u2013s46 (2021).","journal-title":"J. Infect. Dis."},{"key":"63508_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/cid\/ciz145","volume":"69","author":"J Reekie","year":"2019","unstructured":"Reekie, J. et al. Risk of ectopic pregnancy and tubal infertility following gonorrhea and chlamydia infections. Clin. Infect. Dis. 69, 1621\u20131623 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"63508_CR5","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","volume":"2","author":"M Unemo","year":"2021","unstructured":"Unemo, M. et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study. Lancet Microbe 2, e627\u2013e636 (2021).","journal-title":"Lancet Microbe"},{"key":"63508_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"M Unemo","year":"2019","unstructured":"Unemo, M. et al. Gonorrhoea. Nat. Rev. Dis. Prim. 5, 79 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"63508_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae053","volume":"6","author":"V Ouk","year":"2024","unstructured":"Ouk, V. et al. High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022-23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP). JAC Antimicrob. Resist. 6, dlae053 (2024).","journal-title":"JAC Antimicrob. Resist."},{"key":"63508_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101125","volume":"48","author":"PT Lan","year":"2024","unstructured":"Lan, P. T. et al. The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) identifies high levels of ceftriaxone resistance across Vietnam, 2023. Lancet Region. Health West. Pac. 48, 101125 (2024).","journal-title":"Lancet Region. Health West. Pac."},{"key":"63508_CR9","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1128\/AAC.46.10.3118-3124.2002","volume":"46","author":"DJ Payne","year":"2002","unstructured":"Payne, D. J. et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118\u20133124 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63508_CR10","first-page":"146","volume":"5","author":"RJ Heath","year":"2004","unstructured":"Heath, R. J. & Rock, C. O. Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs 5, 146\u2013153 (2004).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"63508_CR11","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1021\/jm301113w","volume":"55","author":"V Gerusz","year":"2012","unstructured":"Gerusz, V. et al. From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria. J. Med. Chem. 55, 9914\u20139928 (2012).","journal-title":"J. Med. Chem."},{"key":"63508_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41564-019-0604-5","volume":"5","author":"EN Parker","year":"2020","unstructured":"Parker, E. N. et al. Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens. Nat. Microbiol. 5, 67\u201375 (2020).","journal-title":"Nat. Microbiol."},{"key":"63508_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nsmb899","volume":"12","author":"FJ Asturias","year":"2005","unstructured":"Asturias, F. J. et al. Structure and molecular organization of mammalian fatty acid synthase. Nat. Struct. Mol. Biol. 12, 225\u2013232 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"63508_CR14","doi-asserted-by":"publisher","first-page":"10579","DOI":"10.1093\/nar\/gku762","volume":"42","author":"CW Remmele","year":"2014","unstructured":"Remmele, C. W. et al. Transcriptional landscape and essential genes of Neisseria gonorrhoeae. Nucleic acids Res. 42, 10579\u201310595 (2014).","journal-title":"Nucleic acids Res."},{"key":"63508_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1074\/jbc.M115.699462","volume":"291","author":"J Yao","year":"2016","unstructured":"Yao, J., Bruhn, D. F., Frank, M. W., Lee, R. E. & Rock, C. O. Activation of exogenous fatty acids to acyl-acyl carrier protein cannot bypass FabI inhibition in Neisseria. J. Biol. Chem. 291, 171\u2013181 (2016).","journal-title":"J. Biol. Chem."},{"key":"63508_CR16","doi-asserted-by":"publisher","first-page":"e00250","DOI":"10.1128\/AAC.00250-20","volume":"64","author":"F Wittke","year":"2020","unstructured":"Wittke, F. et al. Afabicin, a first-in-class antistaphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical noninferiority to vancomycin\/linezolid. Antimicrob. Agents Chemother. 64, e00250\u201300220 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63508_CR17","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1128\/AAC.01741-15","volume":"60","author":"B Hafkin","year":"2015","unstructured":"Hafkin, B., Kaplan, N. & Murphy, B. Efficacy and safety of AFN-1252, the first staphylococcus-specific antibacterial agent, in the treatment of acute bacterial skin and skin structure infections, including those in patients with significant comorbidities. Antimicrob. Agents Chemother. 60, 1695\u20131701 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63508_CR18","doi-asserted-by":"crossref","unstructured":"Unemo, M. et al. The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains\u2014phenotypic, genetic and reference genome characterisation. J. Antimicrob. Chemother. 79, 1885\u20131899 (2024).","DOI":"10.1093\/jac\/dkae176"},{"key":"63508_CR19","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","volume":"25","author":"SF Altschul","year":"1997","unstructured":"Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic acids Res. 25, 3389\u20133402 (1997).","journal-title":"Nucleic acids Res."},{"key":"63508_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/infdis\/173.3.636","volume":"173","author":"MA Apicella","year":"1996","unstructured":"Apicella, M. A. et al. The pathogenesis of gonococcal urethritis in men: confocal and immunoelectron microscopic analysis of urethral exudates from men infected with Neisseria gonorrhoeae. J. Infect. Dis. 173, 636\u2013646 (1996).","journal-title":"J. Infect. Dis."},{"key":"63508_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1128\/IAI.67.3.1149-1156.1999","volume":"67","author":"GA Jarvis","year":"1999","unstructured":"Jarvis, G. A., Li, J. & Swanson, K. V. Invasion of human mucosal epithelial cells by Neisseria gonorrhoeae upregulates expression of intercellular adhesion molecule 1 (ICAM-1). Infect. Immun. 67, 1149\u20131156 (1999).","journal-title":"Infect. Immun."},{"key":"63508_CR22","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1128\/AAC.01411-12","volume":"56","author":"N Kaplan","year":"2012","unstructured":"Kaplan, N. et al. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob. Agents Chemother. 56, 5865\u20135874 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63508_CR23","doi-asserted-by":"crossref","unstructured":"Masuko, A. et al. In vitro and in vivo activities of TP0480066, a novel topoisomerase inhibitor, against Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 65, e02145\u201320 (2021).","DOI":"10.1128\/AAC.02145-20"},{"key":"63508_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0378-5173(03)00287-4","volume":"261","author":"T Heimbach","year":"2003","unstructured":"Heimbach, T. et al. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. Int. J. Pharm. 261, 81\u201392 (2003).","journal-title":"Int. J. Pharm."},{"key":"63508_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrd2468","volume":"7","author":"J Rautio","year":"2008","unstructured":"Rautio, J. et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Disc. 7, 255\u2013270 (2008).","journal-title":"Nat. Rev. Drug Disc."},{"key":"63508_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrd.2018.46","volume":"17","author":"J Rautio","year":"2018","unstructured":"Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Disc. 17, 559\u2013587 (2018).","journal-title":"Nat. Rev. Drug Disc."},{"key":"63508_CR27","doi-asserted-by":"crossref","unstructured":"McComb, R., Bowers, G. & Posen, S. Alkaline Phosphatase. Vol. 9, 986 (Plenum Press, 1979).","DOI":"10.1007\/978-1-4613-2970-1"},{"key":"63508_CR28","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1124\/dmd.108.026245","volume":"37","author":"H Yuan","year":"2009","unstructured":"Yuan, H., Li, N. & Lai, Y. Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs. Drug Metab. disposition: Biol. Fate Chem. 37, 1443\u20131447 (2009).","journal-title":"Drug Metab. disposition: Biol. Fate Chem."},{"key":"63508_CR29","doi-asserted-by":"crossref","unstructured":"Connolly, K. L. et al. Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model. Antimicrob. Agents Chemother. 63, e01644\u201318 (2019).","DOI":"10.1128\/AAC.01644-18"},{"key":"63508_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep11827","volume":"5","author":"GS Basarab","year":"2015","unstructured":"Basarab, G. S. et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci. Rep. 5, 11827 (2015).","journal-title":"Sci. Rep."},{"key":"63508_CR31","doi-asserted-by":"crossref","unstructured":"Bulik, C. C. et al. Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against Gram-positive organisms using data from murine infection models. Antimicrob. Agents Chemother. 61, e00115\u201316 (2017).","DOI":"10.1128\/AAC.00115-16"},{"key":"63508_CR32","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1128\/AAC.01565-10","volume":"55","author":"A Louie","year":"2011","unstructured":"Louie, A., Liu, W., Kulawy, R. & Drusano, G. L. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob. Agents Chemother. 55, 3453\u20133460 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63508_CR33","doi-asserted-by":"crossref","unstructured":"Silver, L. L. Appropriate targets for antibacterial drugs. Cold Spring Harb. Perspect. Med. 6, a030239 (2016).","DOI":"10.1101\/cshperspect.a030239"},{"key":"63508_CR34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.coph.2008.06.008","volume":"8","author":"H Br\u00f6tz-Oesterhelt","year":"2008","unstructured":"Br\u00f6tz-Oesterhelt, H. & Brunner, N. A. How many modes of action should an antibiotic have?. Curr. Opin. Pharmacol. 8, 564\u2013573 (2008).","journal-title":"Curr. Opin. Pharmacol."},{"key":"63508_CR35","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/acscentsci.2c00598","volume":"8","author":"EN Parker","year":"2022","unstructured":"Parker, E. N. et al. An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections. ACS Cent. Sci. 8, 1145\u20131158 (2022).","journal-title":"ACS Cent. Sci."},{"key":"63508_CR36","doi-asserted-by":"publisher","first-page":"36261","DOI":"10.1074\/jbc.M113.512905","volume":"288","author":"J Yao","year":"2013","unstructured":"Yao, J., Maxwell, J. B. & Rock, C. O. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). J. Biol. Chem. 288, 36261\u201336271 (2013).","journal-title":"J. Biol. Chem."},{"key":"63508_CR37","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.str.2012.03.013","volume":"20","author":"J Schiebel","year":"2012","unstructured":"Schiebel, J. et al. Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality. Structure 20, 802\u2013813 (2012).","journal-title":"Structure"},{"key":"63508_CR38","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1021\/acs.jcim.2c01178","volume":"62","author":"VG Maltarollo","year":"2022","unstructured":"Maltarollo, V. G. et al. Do go chasing waterfalls: Enoyl reductase (FabI) in complex with inhibitors stabilizes the tetrameric structure and opens water channels. J. Chem. Inf. Model. 62, 5746\u20135761 (2022).","journal-title":"J. Chem. Inf. Model."},{"key":"63508_CR39","doi-asserted-by":"publisher","first-page":"23175","DOI":"10.1021\/acsomega.0c02942","volume":"5","author":"R Demissie","year":"2020","unstructured":"Demissie, R., Kabre, P. & Fung, L. W. Nonactive-site mutations in S. aureus FabI that induce triclosan resistance. ACS Omega 5, 23175\u201323183 (2020).","journal-title":"ACS Omega"},{"key":"63508_CR40","doi-asserted-by":"crossref","unstructured":"Igawa, G. et al. Neisseria cinerea with high ceftriaxone MIC is a source of ceftriaxone and cefixime resistance-Mmdiating penA sequences in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 62, e02069\u201317 (2018).","DOI":"10.1128\/AAC.02069-17"},{"key":"63508_CR41","doi-asserted-by":"publisher","first-page":"e0199122","DOI":"10.1128\/mbio.01991-22","volume":"13","author":"M Goytia","year":"2022","unstructured":"Goytia, M. & Wadsworth, C. B. Canary in the coal mine: How resistance surveillance in commensals could help curb the spread of AMR in pathogenic Neisseria. mBio 13, e0199122 (2022).","journal-title":"mBio"},{"key":"63508_CR42","doi-asserted-by":"crossref","unstructured":"Wadsworth, C. B., Arnold, B. J., Sater, M. R. A. & Grad, Y. H. Azithromycin resistance through interspecific acquisition of an epistasis-dependent efflux pump component and transcriptional regulator in Neisseria gonorrhoeae. mBio 9, e01419\u201318 (2018).","DOI":"10.1128\/mBio.01419-18"},{"key":"63508_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF00182388","volume":"34","author":"BG Spratt","year":"1992","unstructured":"Spratt, B. G., Bowler, L. D., Zhang, Q. Y., Zhou, J. & Smith, J. M. Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species. J. Mol. Evol. 34, 115\u2013125 (1992).","journal-title":"J. Mol. Evol."},{"key":"63508_CR44","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/infdis\/jiab211","volume":"224","author":"KL Connolly","year":"2021","unstructured":"Connolly, K. L. et al. Preclinical testing of vaccines and therapeutics for gonorrhea in female mouse models of lower and upper reproductive tract infection. J. Infect. Dis. 224, S152\u2013s160 (2021).","journal-title":"J. Infect. Dis."},{"key":"63508_CR45","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.cell.2020.05.005","volume":"181","author":"JK Martin 2nd","year":"2020","unstructured":"Martin, J. K. 2nd et al. A dual-mechanism antibiotic kills Gram-negative bacteria and avoids drug resistance. Cell 181, 1518\u20131532.e1514 (2020).","journal-title":"Cell"},{"key":"63508_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22012-7","volume":"12","author":"ZD Aron","year":"2021","unstructured":"Aron, Z. D. et al. trans-Translation inhibitors bind to a novel site on the ribosome and clear Neisseria gonorrhoeae in vivo. Nat. Commun. 12, 1799 (2021).","journal-title":"Nat. Commun."},{"key":"63508_CR47","doi-asserted-by":"publisher","first-page":"15537","DOI":"10.1021\/acs.jmedchem.4c01187","volume":"67","author":"MS Youse","year":"2024","unstructured":"Youse, M. S. et al. Optimization of ethoxzolamide analogs with improved pharmacokinetic properties for in vivo efficacy against Neisseria gonorrhoeae. J. Med. Chem. 67, 15537\u201315556 (2024).","journal-title":"J. Med. Chem."},{"key":"63508_CR48","doi-asserted-by":"publisher","first-page":"105454","DOI":"10.1016\/j.micpath.2022.105454","volume":"164","author":"NS Abutaleb","year":"2022","unstructured":"Abutaleb, N. S., Elhassanny, A. E. M. & Seleem, M. N. In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection. Microb. Pathogenesis 164, 105454 (2022).","journal-title":"Microb. Pathogenesis"},{"key":"63508_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266764","volume":"17","author":"AEM Elhassanny","year":"2022","unstructured":"Elhassanny, A. E. M., Abutaleb, N. S. & Seleem, M. N. Auranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infection. PLoS ONE 17, e0266764 (2022).","journal-title":"PLoS ONE"},{"key":"63508_CR50","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/jac\/dkq289","volume":"65","author":"SA Chisholm","year":"2010","unstructured":"Chisholm, S. A. et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. J. Antimicrob. Chemother. 65, 2141\u20132148 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"63508_CR51","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1093\/clinids\/20.Supplement_1.S47","volume":"20","author":"JS Moran","year":"1995","unstructured":"Moran, J. S. & Levine, W. C. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin. Infect. Dis. 20, S47\u2013S65 (1995).","journal-title":"Clin. Infect. Dis."},{"key":"63508_CR52","unstructured":"World Health Organization Target Product Profile for Therapy of Diagnosed Uncomplicated Gonorrhoea. (JSTOR, 2020)."},{"key":"63508_CR53","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1016\/j.bmcl.2009.07.094","volume":"19","author":"J Ramnauth","year":"2009","unstructured":"Ramnauth, J. et al. 2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI. Bioorg. Med. Chem. Lett. 19, 5359\u20135362 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"63508_CR54","unstructured":"Gerusz, V. et al. WO2020099341 Antibiotic Compounds, Methods of Manufacturing the Same, Pharmaceutical Compositions Containing the Same and Uses Thereof. WO\/2020\/099341, WIPO (2020)."},{"key":"63508_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. Sect. D., Biol. Crystallogr. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. Sect. D., Biol. Crystallogr."},{"key":"63508_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. Sect. D. Biol. Crystallogr. 67, 293\u2013302 (2011).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"63508_CR57","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1107\/S2059798323003595","volume":"79","author":"J Agirre","year":"2023","unstructured":"Agirre, J. et al. The CCP4 suite: integrative software for macromolecular crystallography. Acta Crystallogr. Sect. D., Struct. Biol. 79, 449\u2013461 (2023).","journal-title":"Acta Crystallogr. Sect. D., Struct. Biol."},{"key":"63508_CR58","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"63508_CR59","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/cbdd.13686","volume":"96","author":"NK Rao","year":"2020","unstructured":"Rao, N. K. et al. Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies. Chem. Biol. Drug Des. 96, 704\u2013713 (2020).","journal-title":"Chem. Biol. Drug Des."},{"key":"63508_CR60","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"63508_CR61","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D. Biol. Crystallogr. 53, 240\u2013255 (1997).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"63508_CR62","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/prot.10286","volume":"50","author":"SC Lovell","year":"2003","unstructured":"Lovell, S. C. et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 50, 437\u2013450 (2003).","journal-title":"Proteins"},{"key":"63508_CR63","unstructured":"CLSI. M07 Methods for Antimicrobial Susceptibility Testing of Aerobic Bacteria, 11th Edition. (Clinical Laboratory Standards Institute, USA, 2018)."},{"key":"63508_CR64","unstructured":"CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing, 13th Edition. (Clinical Laboratory Standards Institute, USA, 2020)."},{"key":"63508_CR65","unstructured":"CLSI. M26-A Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved guideline. (Clinical Laboratory Standards Institute, USA, 1999)."},{"key":"63508_CR66","doi-asserted-by":"publisher","first-page":"W521","DOI":"10.1093\/nar\/gkae241","volume":"52","author":"F Madeira","year":"2024","unstructured":"Madeira, F. et al. The EMBL-EBI Job Dispatcher sequence analysis tools framework in 2024. Nucleic Acids Res. 52, W521\u2013w525 (2024).","journal-title":"Nucleic Acids Res."},{"key":"63508_CR67","doi-asserted-by":"publisher","first-page":"W78","DOI":"10.1093\/nar\/gkae268","volume":"52","author":"I Letunic","year":"2024","unstructured":"Letunic, I. & Bork, P. Interactive Tree of Life (iTOL) v6: recent updates to the phylogenetic tree display and annotation tool. Nucleic Acids Res. 52, W78\u2013w82 (2024).","journal-title":"Nucleic Acids Res."},{"key":"63508_CR68","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1128\/AAC.00564-13","volume":"57","author":"J Mallegol","year":"2013","unstructured":"Mallegol, J., Fernandes, P., Seah, C., Guyard, C. & Melano, R. G. Determination of in vitro activities of solithromycin at different pHs and its intracellular activity against clinical isolates of Neisseria gonorrhoeae from a laboratory collection. Antimicrob. Agents Chemother. 57, 4322\u20134328 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63508_CR69","first-page":"133","volume":"219","author":"P Lu","year":"2019","unstructured":"Lu, P. et al. A subpopulation of intracellular Neisseria gonorrhoeae escapes autophagy-mediated killing inside epithelial cells. J. Infect. Dis. 219, 133\u2013144 (2019).","journal-title":"J. Infect. Dis."},{"key":"63508_CR70","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/nprot.2007.303","volume":"2","author":"I Hubatsch","year":"2007","unstructured":"Hubatsch, I., Ragnarsson, E. G. & Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2, 2111\u20132119 (2007).","journal-title":"Nat. Protoc."},{"key":"63508_CR71","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejps.2014.02.008","volume":"56","author":"Y Peng","year":"2014","unstructured":"Peng, Y., Yadava, P., Heikkinen, A. T., Parrott, N. & Railkar, A. Applications of a 7-day Caco-2 cell model in drug discovery and development. Eur. J. Pharm. Sci. 56, 120\u2013130 (2014).","journal-title":"Eur. J. Pharm. Sci."},{"key":"63508_CR72","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0027-5107(00)00065-8","volume":"455","author":"M Fenech","year":"2000","unstructured":"Fenech, M. The in vitro micronucleus technique. Mutat. Res. 455, 81\u201395 (2000).","journal-title":"Mutat. Res."},{"key":"63508_CR73","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0165-1161(75)90046-1","volume":"31","author":"BN Ames","year":"1975","unstructured":"Ames, B. N., McCann, J. & Yamasaki, E. Methods for detecting carcinogens and mutagens with the Salmonella\/mammalian-microsome mutagenicity test. Mutat. Res. 31, 347\u2013364 (1975).","journal-title":"Mutat. Res."},{"key":"63508_CR74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0027-5107(79)90195-7","volume":"59","author":"D Clive","year":"1979","unstructured":"Clive, D., Johnson, K. O., Spector, J. F., Batson, A. G. & Brown, M. M. Validation and characterization of the L5178Y\/TK+\/\u2212 mouse lymphoma mutagen assay system. Mutat. Res. 59, 61\u2013108 (1979).","journal-title":"Mutat. Res."},{"key":"63508_CR75","unstructured":"National Research Council. Guide for the care and use of laboratory animals (National Academies Press, 2011)."},{"key":"63508_CR76","unstructured":"EUCAST. Breakpoint Tables for interpretation of MICs and zone diameters, version 14.0. (EUCAST, 2020)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63508-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:03:48Z","timestamp":1758186228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63508-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63508"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63508-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.G., V.T., M.S., J.B., and T.F. are listed as inventors on the patent application WO2020099341 \u201cAntibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof\u201d which covers compound 2, Debio 1453 and Debio 1453P listed in this manuscript. V.G., P.R., Q.R., V.M., M.G., R.L., A.A., D.P., M.M., were each employees of Debiopharm Research and Manufacturing SA. J.D., X.L., J.H.P., L.F.D., J.B., G.D., T.F., P.D., F.B., and D.R.C. were each employees of Debiopharm International SA. S.D. and N.K. were paid consultants of Debiopharm International SA. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8309"}}